Roche floats record-setting $16B bond issue

For us pharma-watchers, today's news that Roche raised $16 billion from a bond sale means that it's that much closer to a takeover of Genentech. But to market-watchers, the debt sale is a sign that the corporate bond market is alive and well. And for recordbook-keepers, the Roche sale was the largest U.S. dollar-denominated corporate bond sale ever.

Fact is, Roche's decision to bypass banks in favor of the bond markets says a couple other things, too: That the Swiss pharma wasn't confident that the troubled banking system could come through to finance the $42 billion buyout--but it is confident of eventually sealing a deal with Genentech. Otherwise, why risk paying interest on billions in bonds?

It's the second big bond sale in pharma this month. You'll recall that Novartis sold $5 billion worth about a week ago, stocking the drugmaker's coffers for "financial flexibility."

- read the story in the Wall Street Journal

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.